---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224238"
form_type: "8-K"
ticker: "RNA"
cik: "0002093101"
company_name: "Atrium Therapeutics, Inc."
filed_at: "2026-05-14T20:50:07+00:00"
generated_at: "2026-05-14T20:51:26.765105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M

## Summary
- Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.
- R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.
- ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.
- Company launched as independent public on Feb 27, 2026 after spin-off from Avidity.

## SEC filing metadata
- accession: 0001193125-26-224238
- form_type: 8-K
- ticker: RNA
- cik: 0002093101
- company_name: Atrium Therapeutics, Inc.
- filed_at: 2026-05-14T20:50:07+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/0001193125-26-224238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/d82207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224238
- JSON: https://secwatch.observer/filing/0001193125-26-224238.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224238.txt

## Key facts
- Earnings Releases
  Atrium Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: Exhibit 99.1 Atrium Therapeutics Reports First Quarter 2026 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/0001193125-26-224238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.